MoCRA Registration for European Cosmetics Brands: What the FDA's Modernization Act Requires Before You Ship to the US

For 84 years, the US Food, Drug, and Cosmetic Act treated cosmetic products with a notably light regulatory touch. Manufacturers could formulate, market, and ship without ever notifying the FDA. No registration. No product listing. No mandatory safety data. The agency’s enforcement role was largely reactive — waiting for something to go wrong before it could act.

That architecture ended on December 29, 2022, when Congress passed the Modernization of Cosmetics Regulation Act — MoCRA — as part of an omnibus spending bill. It’s the most consequential change to US cosmetics law in living memory, and its implications for European brands exporting to the US have been consistently underestimated.

The assumption we hear most often: our EU compliance covers it. A complete Cosmetic Product Safety Report, a signed assessment from a qualified toxicologist, a Responsible Person duly designated in an EU member state — that’s rigorous work, and it matters. But it does not constitute FDA registration. MoCRA created a parallel framework, and it applies to every foreign manufacturer shipping cosmetics into US commerce, without exception.

What MoCRA Actually Built — And What the Old Law Didn’t Have

Before MoCRA, the contrast between EU and US cosmetics regulation was almost uncomfortable to describe. The EU Cosmetics Regulation (EC) No 1223/2009 maintains Annex II with over 1,600 prohibited substances, Annex III with more than 300 restricted ones, mandatory pre-market safety assessments, and a product notification system through the CPNP portal. The FDA, by comparison, had express authority to prohibit exactly 11 ingredients from cosmetics — eleven, in a market now generating roughly $100 billion in annual sales.

MoCRA didn’t close that gap overnight, but it established the infrastructure to do so. The law created four core compliance obligations that now apply to any brand marketing cosmetics in the US:

1. Facility registration for every site that manufactures or processes cosmetics sold in the US market
2. Product listing for every cosmetic product marketed in the US
3. Serious adverse event reporting within a defined timeframe
4. Safety substantiation — maintaining records demonstrating that each product is safe under its labeled conditions of use

The FDA is also developing implementing GMP regulations (rulemaking is ongoing), and further rules on fragrance allergen disclosure are expected. The foundation, however, is already in place and already enforceable.

The Registration Deadlines That Already Passed — And What Comes Next

The compliance calendar for MoCRA moved quickly. Large facilities — those not qualifying as small businesses — were required to register with the FDA by December 29, 2023, exactly one year after MoCRA’s enactment. Small businesses, defined under the Act as companies with average annual gross sales of cosmetics in the US under $1,000,000 in the preceding 3-year period, had until July 1, 2024.

Facilities that commenced manufacturing or processing cosmetics for US distribution after December 29, 2022, must register within 60 days of beginning operations. And registration isn’t a one-time event — it must be renewed biennially, and lapses if not renewed on schedule.

Product listing runs on the same schedule and carries its own data requirements. Each listed product must include the product name, applicable FDA product category, the name and contact information of the responsible person, registration numbers for all manufacturing and processing facilities involved, and — critically — a complete ingredient list including fragrance components, flavors, and colors identified by their specific names.

That last point is a recurring problem for European brands. EU labelling rules permit “parfum” as a single label entry for most fragrance compounds, with specific allergen disclosures required only for the 26 listed substances above threshold concentrations. MoCRA’s product listing requirements push in the opposite direction: full ingredient transparency by specific name. Brands whose formulations were designed with EU label architecture in mind will need to revisit ingredient disclosure before completing their US product listings.

The US Agent Requirement: More Than a Mailing Address

Foreign manufacturers — which includes every cosmetics brand manufacturing in France, Germany, Italy, Spain, or anywhere else in the EU — must designate a US agent under MoCRA. This person or entity must be physically located in the United States and serves as the FDA’s primary contact for inspections, regulatory communications, and adverse event coordination.

This is a substantive role, not a procedural checkbox. The US agent needs genuine regulatory competence: the ability to receive and respond to FDA communications in a timely way, an understanding of how MoCRA obligations work in practice, and the capacity to coordinate with the brand’s European team during a regulatory interaction. A logistics partner or freight forwarder almost never qualifies unless they’ve specifically taken on these functions by contract and have the internal expertise to perform them.

For European brands that don’t have a US subsidiary or regulatory affiliate, routing this obligation through a partner network — one that combines US agent functions with product listing support and laboratory testing — is typically the most efficient path. It also ensures continuity when the FDA sends requests that require a substantive response rather than just a forwarding address.

Serious Adverse Event Reporting: The 15-Business-Day Clock

This is the obligation that most European brands haven’t operationalised — and the one that creates the most acute exposure once products are live in the US market.

Under MoCRA, the responsible person for a cosmetic product must submit a report to the FDA within 15 business days of first receiving information about a serious adverse event associated with the product’s use in the US. A serious adverse event is defined as one resulting in death, a life-threatening experience, inpatient hospitalisation, a persistent or significant disability or incapacity, a congenital anomaly or birth defect, or significant disfigurement — including serious or persistent rashes, significant hair loss, or severe scalp irritation.

The reporting mechanism is FDA’s MedWatch system (Form FDA 3500A), and records of all adverse events — serious and non-serious — must be maintained for 6 years.

This triggers real operational questions for a European brand with products on Amazon.com, through US retail distributors, or via a DTC e-commerce channel targeting US consumers. Who in your organisation monitors US consumer communications? Do your distributor agreements explicitly require US partners to forward consumer complaints to you — and do those agreements define which complaints trigger the 15-business-day clock? If you’re selling on a marketplace, are you actively monitoring product reviews for safety signals that could constitute adverse event reports?

Most EU compliance programmes weren’t designed with this kind of US-facing consumer surveillance in mind. Building it retroactively, after a serious complaint arrives, is far harder than designing it as part of market entry.

Does Your EU Safety Documentation Satisfy MoCRA?

The honest answer: partially, and in some areas not at all.

Your Cosmetic Product Safety Report (CPSR) — the toxicological assessment prepared by a qualified person under Regulation (EC) No 1223/2009 — is a rigorous demonstration of safety substantiation. The FDA doesn’t require a CPSR format specifically, but it does require that responsible persons maintain records showing the product is safe under labeled and customary conditions of use. A well-prepared CPSR is strong substantive evidence. It isn’t, however, a substitute for registration, listing, or adverse event reporting — those are procedural obligations the CPSR simply doesn’t address.

Where EU documentation maps to MoCRA requirements, and where it doesn’t:

EU Obligation	MoCRA Equivalent	Transfers Directly?
Product Information File (PIF)	Product Listing	Partial — data fields differ significantly
Cosmetic Product Safety Report (CPSR)	Safety substantiation records	Partial — content helps, but format is not required
Responsible Person (EU-based)	US Responsible Person / US Agent	No — separate designation required
CPNP Notification	FDA Product Listing	No — entirely separate submission
Annex VII colorant notifications	Ingredient listing in product listing	Partial

One more nuance worth flagging before market entry: EU-prohibited ingredients and US-restricted ingredients don’t fully overlap. A formula that’s clean under EU Annex II and Annex III may include substances under active FDA scrutiny in the US. Running a bilateral ingredient screen before entering the US market isn’t optional due diligence — it’s baseline risk management.

Before Your Next US Shipment: Six Things to Confirm

If you’re a European cosmetics brand planning US market entry — or already selling in the US and uncertain about your MoCRA status — here’s where to focus your compliance review:

1. Verify facility registration for every site that manufactures or processes your products, including EU-based contract manufacturers. Their location is irrelevant; if they make products that enter US commerce, they must be registered with the FDA.
2. Complete product listings through the FDA’s Cosmetics Direct portal for every product currently marketed in the US. Missing listings mean you’re selling unlisted products — a prohibited act under the amended FD&C Act.
3. Designate a US agent with genuine regulatory competence. Document the designation formally and ensure your US agent understands their responsibilities under MoCRA, not just their contact details.
4. Audit your adverse event procedures: map who receives US consumer complaints, which threshold triggers a serious adverse event assessment, and how the 15-business-day reporting clock gets activated and tracked.
5. Review your ingredient disclosures against MoCRA product listing requirements — particularly fragrance and flavor components that may be listed collectively in EU documentation.
6. Run a bilateral ingredient screen to identify any formulation components that are permitted under EU Regulation 1223/2009 but flagged under current or proposed US restrictions.

The FDA has been increasing its MoCRA-related outreach and has signalled that enforcement activity will intensify as the post-deadline period lengthens. Registration gaps, missing product listings, and absent adverse event procedures are all documentable violations. The question isn’t whether enforcement will reach your products — it’s whether you’ll have corrected course before it does.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry. Contact us

Related from our network

• FDA cosmetics compliance testing and ISO 17025 laboratory support for US market entry — Qalitex Laboratories provides the safety substantiation testing and documentation that MoCRA requires for cosmetics sold in the US.
• Health Canada compliance for European cosmetics and natural health products entering Canada — Androxa supports European brands navigating Canadian NHPD and NHP registration requirements alongside US market entry.